HCAs are benign liver tumors that are most often observed among women of childbearing age and that are highly associated with exposure to estrogens, including OCPs. An incidence of HCAs is 30-40 times more likely to occur among OCP users than non-users of the drugs. Even though HCAs are less common with OCP dosage reductions, obesity, metabolic syndrome, and steroids usage are now known causative agents. HCAs include glycogen storage diseases (GSDs), polycystic ovarian syndrome (PCOS), Klinefelter syndrome and others.
In men, obesity raises the risk of dying from hepatocellular carcinoma in patients with HCAs to a level beyond what metabolic syndrome does. HCAs can be solitary or multiple and can occasionally be larger than 20 cm in size Single β–catenin HCAs are at higher risk of developing both malignant transformation and hemorrhage.
Hepatocellular adenomas (HCAs) are very rare and are found in < 0.007- 0.012% of population. In women who do not use OCPs the incidence is calculated between 1 and 1.3 per million; for women using OCPs, the rate increases to 34 per million, with the risk being proportional to the period and the amount of estrogen. Although first- and second-generation contraceptives have been replaced by low-dose products, HCA have become more easily identified because of increased use of imaging techniques and the obesity and metabolic syndrome epidemics.
Regarding the gender distribution, the HCAs are not related to race, but the data from 1998 to 2008 present a male predominance in China because of the one-child policy and the non-availability of OCP, while female patients dominate the HCA cases in other zones. Approximately 90% of HCA cases are reported to have affected women whereas men, HCA is related with anabolic steroids and glycogen storage diseases.
Epidemiology
Hepatocellular adenomas (HCAs) or hepatic adenomas are extremely rare and are reported in people with a prevalence of less than 0.007- 0.012% of the population. In women not using OC pills, the incidence rate is estimated at ranges from 1 to 1.3 women per one million women. For women on OCPs, this rate becomes roughly 34 per million, with the probability rising depending on the dose of estrogen and length of usage. Lower-dose contraceptives may now be seen more often because medical imaging is more widely used, obesity and metabolic syndrome are becoming more common.
They are not based on race, though a review from 1998-2008 showed a male majority among the Chinese, unlike females in other regions, probably due to birth control. HCA tumors mostly affect females with approximately 90% while in males, the tumors are associated with anabolic androgen steroids use and glycogen storage disease. Among them, the β-HCA subtype, commonly arising in males, has worse prognosis, and a higher incidence of malignancy. HCAs often occur in patients between 20 and 50 years of age.
Anatomy
Pathophysiology
In 1973, Baum et al suggested that OCPs had a relationship with HCAs, and both male and female hormones have been implicated in the formation of these tumours. HCAs are commonly associated with increased estrogen receptors in breast cancer, although this matter is still a subject of debate, as some HCAs may arise with no apparent risk factors. HCAs are assumed to be caused by genetic changes and environmental factors OCP and steatosis. Many genetic changes characterize different subtypes of HCA and all of them have different associations with the disease. The H-HCA subtype is inactivated by hepatocyte nuclear factor 1α and is related to diabetes and liver adenomatosis; the I-HCAs are associated with mutations in the JAK/STAT pathway, obesity, and alcohol use.
The β-HCAs involving the CTNNB1 gene yield higher risks of malignancy; such risks are accentuated in males, though the model is less statistically valid in male populations. More recent studies have even established up to eight HCA subtypes because knowledge of its progression is crucial. In glycogen storage diseases (GSD), type I-HCA is prevalent, and changes in diet might contribute towards reducing tumor progression. However, mutations on some chromosomes still predispose individuals to develop HCC. These hormones include insulin and glucagon and in some families with diabetes and liver adenomatosis HNF1α gene is mutated.
Etiology
Chen et al. contributed to further knowledge in Hepatocellular adenoma (HCA) genesis in their work published in 2002 with the understanding that β-catenin is the Wnt signaling pathway. In their subsequent work, Bioulac-Sage and colleagues have designed a classification system based on the molecular characteristics that have been also confirmed by other authors. This system divides HCAs into four main types:
Hepatocyte Nuclear Factor-1α (HNF-1α) Inactivated Mutations: These mutations contribute to 35-40 percent of HCA incidences and include T-cell factor-1 gene responsible for liver differentiation, glucose, and lipid homeostasis. The lesions are steatotic, affect mainly women, and may be related to diseases such as MODY3 diabetes. A size of tumor below 5 cm does not contribute to the development of complications.
β-Catenin Activated Mutations: These adenomas form 15–20 percent of the cases and are associated with androgen, glycogen storage disease and familial adenomatous polyposis. These lesions are more likely to become malignant and are diagnosed by glutamine synthetase & aberrant β-catenin staining.
Inflammatory Hepatocellular Adenomas (IHCA): IHCA is found in 40-50% of the cases and is linked with risk factors including female sex, obesity, alcohol use, & conditions that cause systemic inflammation. Consequently, alteration of the IL-6 pathway in ADA-SCID results in unique vascular and sinusoidal features.
Unclassified Type: It is estimated that less than 10% of HCAs are of this kind; these present with liver-specific neoplastic tumors that have either lost marker such as CRP, SAA, β-catenin, and glutamine synthetase but express LFABP.
Genetics
Prognostic Factors
The outcome of patients HCA is slightly unclear and depends on the results of imaging and other invasive studies depending upon the tumor type. Cessation of OCPs may result in regression or resolution of some adenomas, however 27% HCAs may continue to rupture and have mortality between 5%-10%. The chances of cancer development are around 4.2%, and such risks remain present even after you cease using oral contraceptives. Patients are unlikely to fully eliminate HCA from their bodies. Around 25% of the females may have RUQ pain after delivery and hemorrhage is seen in 30 to 45 percent of women. Bleeding can occur within the tumor or into the peritoneal cavity; the risk of hemorrhage is proportional to the size of the lesion. Pregnancy is also associated with the increase in the size of HCA and the elevated risk of its rupture.
Clinical History
Physical Examination
Abdominal Examination: The patient’s abdomen may be tender, or an enlarged abdomen may be present. Abdominal examination may be associated with right upper quadrant pain on palpation or percussion if there is hemorrhage or large tumor.
Hepatomegaly: Liver may be enlarged and tender, but in most cases of hepatic adenomas the lesion is not palpable.
Signs of Hemorrhage: In cases of acute hemorrhage probable manifestations of shock, the patient may present low blood pressure and tachycardia. Tenderness may be felt in the abdomen and there can be localised or generalised guarding or rebound tenderness if bleeding has occurred and caused peritoneal irritation.
Jaundice: However, jaundice could be seen in some cases of benign HCA but more frequently in malignant transformation or hepatic failures.
Age group
Associated comorbidity
Oral Contraceptive Use: The most important risk factor which is more apparent in women with long term use of high dosage OCPs. Anabolic-Androgenic Steroid (AAS) Use: Affecting males frequently and those men who take anabolic steroids to build muscles.
Metabolic Disorders: Fatty liver diseases, including obesity, metabolic syndrome, diabetes mellitus, and glycogen storage diseases (GSD) are associated with HCA formation.
Pregnancy: It has been attributed to hormonal changes that cause adenoma to enlarge and be inclined towards rupture.
Alcohol Consumption: Another modifiable risk factor is high alcohol consumption strictly linked to inflammatory HCAs.
Associated activity
Acuity of presentation
HCA can present with acute complications such as:
Hemorrhage: In 30-45% of cases bleeding develops inside a tumor or in the peritoneal cavity. This risk is higher in larger adenomas and in pregnancy.
Rupture: Can cause severe condition known as acute hemorrhagic shock and presents clinically as sudden severe abdominal pain, hypotension and evident features of bleeding.
Differential Diagnoses
Hepatocellular Carcinoma (HCC)
Metastatic Cancer with Unknown Primary Site
Cholangiocarcinoma
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
Treatment Paradigm
Observation and Monitoring: Where the HCA is small and largely asymptomatic, measuring 4 to 5 centimetres or less and showing no signs of growth, observation might be adequate. Physical examination can be done periodically depending on the patient, but imaging (ultrasound, CT or MRI) should be obtained every 6-12 months.
Medical Management Oral Contraceptive Pill (OCP) Discontinuation: In females, cessation of OCP, led to the regression of the adenoma, especially in females with HCA due to hormonal factors.
Interventional Procedures Ablation Techniques: In bigger or symptomatic HCAs, other demanding procedures like radiofrequency ablation (RFA) or microwave ablation can be done. These are especially important for the patients who cannot undergo surgeries.
Transarterial Embolization (TAE): This procedure may be done in cases of symptomatic adenomas, particularly those adenomas with a propensity to bleed.
Surgical Intervention: For the potential application of surgery the following features are considered significant: Large HCAs (>4-5 cm) HCA that present symptoms, namely pain or haemorrhage. Atypical lipomatous tumor/was and lipomatous component of mixed malignant neoplasms with suspicious malignant transformation.
Liver Transplantation: For instance, if the patient has the adenoma in combination with cirrhosis, then liver transplantation can be done depends on the degree of liver pathology. Follow-Up Care: Routine imaging follow-up is essential for the monitoring of any sign of disease progression or reappearance of the adenoma.
Lifestyle Changes: Healthy weight and weight management is known to improve the prognosis of HCA; therefore, overweight and obese patients should try to lose weight. It also important to recommend that people should avoid or at least take limited alcohol intake to avoid harming their liver.
Physical Activity: Exercise also has therapeutic value in metabolic syndromes because it enhances metabolic functions and decreases hepatic steatosis and thus may slow the progression of HCA.
Hormonal Management: In women, loss of HCAs when they come off oral contraceptives can cause regression therefore, regular follow up should be done.
Comorbidity Management: The risks can be lowered by managing such factors as diabetes and metabolic syndrome by diet and drugs.
Role of Discontinuation of Oral Contraceptives in the treatment of hepatocellular adenomas
The discontinuation of OCPs forms a major component in the treatment of HCA particularly in women whose tumours have been established to be related to the use of these hormonal contraceptives. The adenomas in women with HCAs associated with OCP use are known to regress or even dissolve on cessation of the contraceptives. HCAs have been found to be self-limiting in about 27% of the cases and the size of lesion may reduce or disappear totally on cessation. OCPs especially those containing high estrogens increase the chances of developing HCAs. Discontinuation may assist in reducing this risk particularly in women who are prone to development of hormone induced liver lesion.
Surgical Resection: Endoscopic resection for adenoma is warranted in those with a size of adenoma greater than 5 cm, adenomas that are symptomatic or give rises to pain or bleeding and those for which malignancy is suspected. In case of a large or locally situated adenoma, partial hepatectomy may be done, that is, the adenoma and a rim of normal liver tissue are excised.
Laparoscopic Resection: This approach is used on smaller adenomas or in patients that would be fit for laparoscopic surgery. Laparoscopic surgery has fewer cuts, together with the aid of a video camera and long, thin instruments to remove the adenoma.
Radiofrequency Ablation (RFA): RFA is done if the adenomas are comparatively small (<3-4 cm), patient is not suitable for surgery or if the patient wants a minimally invasive treatment modality. This technique incorporates radiofrequency generated heat to cause ablation of the adenoma tissue.
Microwave Ablation (MWA): Like for RFA, MWA is used for small lesions and has favor of having shorter ablation times. It uses microwave energy in heating tissue and destroying the tumor. The study also pointed out the possible increased success rate of MWA compared to RFA for bigger tumor size.
Transarterial Chemoembolization (TACE): TACE has been described predominantly in the management of hepatocellular carcinoma but could be considered in the management of an HCA in patients with a bleeding risk or inoperable adenomas. This comprises the delivery of chemotherapy in the blood vessels feeding the adenoma with subsequent deployment of embolic agents, hence promoting ischemia.
The management of hepatocellular adenoma (HCA) involves several phases which play important steps in the process. Diagnosis is accomplished through imaging and biopsy in which the HCA is identified, and its features determined. The assessment phase is geared toward assessment of the patient’s general condition and risks factors such as, lifestyle and hormones. In the treatment phase, the management depends on the size of the adenoma and the symptoms of the patient; the options may include medicinal management, close follow up or surgical management. The second one is the post treatment period where the patient is closely followed up for signs of relapse and complications through imaging and symptoms. Lastly, the maintenance phase focuses on the regular follow-ups and necessary dietary changes in order to prevent the return of cancer besides caring for the liver health in general. All the phases play an important role in patient care, and successful outcomes as well as the overall management of HCA.
»
Home » CAD » Hepatocellular Adenoma (Hepatic Adenoma)
Hepatocellular Adenoma (Hepatic Adenoma)
Updated :
October 14, 2024
HCAs are benign liver tumors that are most often observed among women of childbearing age and that are highly associated with exposure to estrogens, including OCPs. An incidence of HCAs is 30-40 times more likely to occur among OCP users than non-users of the drugs. Even though HCAs are less common with OCP dosage reductions, obesity, metabolic syndrome, and steroids usage are now known causative agents. HCAs include glycogen storage diseases (GSDs), polycystic ovarian syndrome (PCOS), Klinefelter syndrome and others.
In men, obesity raises the risk of dying from hepatocellular carcinoma in patients with HCAs to a level beyond what metabolic syndrome does. HCAs can be solitary or multiple and can occasionally be larger than 20 cm in size Single β–catenin HCAs are at higher risk of developing both malignant transformation and hemorrhage.
Hepatocellular adenomas (HCAs) are very rare and are found in < 0.007- 0.012% of population. In women who do not use OCPs the incidence is calculated between 1 and 1.3 per million; for women using OCPs, the rate increases to 34 per million, with the risk being proportional to the period and the amount of estrogen. Although first- and second-generation contraceptives have been replaced by low-dose products, HCA have become more easily identified because of increased use of imaging techniques and the obesity and metabolic syndrome epidemics.
Regarding the gender distribution, the HCAs are not related to race, but the data from 1998 to 2008 present a male predominance in China because of the one-child policy and the non-availability of OCP, while female patients dominate the HCA cases in other zones. Approximately 90% of HCA cases are reported to have affected women whereas men, HCA is related with anabolic steroids and glycogen storage diseases.
Hepatocellular adenomas (HCAs) or hepatic adenomas are extremely rare and are reported in people with a prevalence of less than 0.007- 0.012% of the population. In women not using OC pills, the incidence rate is estimated at ranges from 1 to 1.3 women per one million women. For women on OCPs, this rate becomes roughly 34 per million, with the probability rising depending on the dose of estrogen and length of usage. Lower-dose contraceptives may now be seen more often because medical imaging is more widely used, obesity and metabolic syndrome are becoming more common.
They are not based on race, though a review from 1998-2008 showed a male majority among the Chinese, unlike females in other regions, probably due to birth control. HCA tumors mostly affect females with approximately 90% while in males, the tumors are associated with anabolic androgen steroids use and glycogen storage disease. Among them, the β-HCA subtype, commonly arising in males, has worse prognosis, and a higher incidence of malignancy. HCAs often occur in patients between 20 and 50 years of age.
In 1973, Baum et al suggested that OCPs had a relationship with HCAs, and both male and female hormones have been implicated in the formation of these tumours. HCAs are commonly associated with increased estrogen receptors in breast cancer, although this matter is still a subject of debate, as some HCAs may arise with no apparent risk factors. HCAs are assumed to be caused by genetic changes and environmental factors OCP and steatosis. Many genetic changes characterize different subtypes of HCA and all of them have different associations with the disease. The H-HCA subtype is inactivated by hepatocyte nuclear factor 1α and is related to diabetes and liver adenomatosis; the I-HCAs are associated with mutations in the JAK/STAT pathway, obesity, and alcohol use.
The β-HCAs involving the CTNNB1 gene yield higher risks of malignancy; such risks are accentuated in males, though the model is less statistically valid in male populations. More recent studies have even established up to eight HCA subtypes because knowledge of its progression is crucial. In glycogen storage diseases (GSD), type I-HCA is prevalent, and changes in diet might contribute towards reducing tumor progression. However, mutations on some chromosomes still predispose individuals to develop HCC. These hormones include insulin and glucagon and in some families with diabetes and liver adenomatosis HNF1α gene is mutated.
Chen et al. contributed to further knowledge in Hepatocellular adenoma (HCA) genesis in their work published in 2002 with the understanding that β-catenin is the Wnt signaling pathway. In their subsequent work, Bioulac-Sage and colleagues have designed a classification system based on the molecular characteristics that have been also confirmed by other authors. This system divides HCAs into four main types:
Hepatocyte Nuclear Factor-1α (HNF-1α) Inactivated Mutations: These mutations contribute to 35-40 percent of HCA incidences and include T-cell factor-1 gene responsible for liver differentiation, glucose, and lipid homeostasis. The lesions are steatotic, affect mainly women, and may be related to diseases such as MODY3 diabetes. A size of tumor below 5 cm does not contribute to the development of complications.
β-Catenin Activated Mutations: These adenomas form 15–20 percent of the cases and are associated with androgen, glycogen storage disease and familial adenomatous polyposis. These lesions are more likely to become malignant and are diagnosed by glutamine synthetase & aberrant β-catenin staining.
Inflammatory Hepatocellular Adenomas (IHCA): IHCA is found in 40-50% of the cases and is linked with risk factors including female sex, obesity, alcohol use, & conditions that cause systemic inflammation. Consequently, alteration of the IL-6 pathway in ADA-SCID results in unique vascular and sinusoidal features.
Unclassified Type: It is estimated that less than 10% of HCAs are of this kind; these present with liver-specific neoplastic tumors that have either lost marker such as CRP, SAA, β-catenin, and glutamine synthetase but express LFABP.
The outcome of patients HCA is slightly unclear and depends on the results of imaging and other invasive studies depending upon the tumor type. Cessation of OCPs may result in regression or resolution of some adenomas, however 27% HCAs may continue to rupture and have mortality between 5%-10%. The chances of cancer development are around 4.2%, and such risks remain present even after you cease using oral contraceptives. Patients are unlikely to fully eliminate HCA from their bodies. Around 25% of the females may have RUQ pain after delivery and hemorrhage is seen in 30 to 45 percent of women. Bleeding can occur within the tumor or into the peritoneal cavity; the risk of hemorrhage is proportional to the size of the lesion. Pregnancy is also associated with the increase in the size of HCA and the elevated risk of its rupture.
Abdominal Examination: The patient’s abdomen may be tender, or an enlarged abdomen may be present. Abdominal examination may be associated with right upper quadrant pain on palpation or percussion if there is hemorrhage or large tumor.
Hepatomegaly: Liver may be enlarged and tender, but in most cases of hepatic adenomas the lesion is not palpable.
Signs of Hemorrhage: In cases of acute hemorrhage probable manifestations of shock, the patient may present low blood pressure and tachycardia. Tenderness may be felt in the abdomen and there can be localised or generalised guarding or rebound tenderness if bleeding has occurred and caused peritoneal irritation.
Jaundice: However, jaundice could be seen in some cases of benign HCA but more frequently in malignant transformation or hepatic failures.
Oral Contraceptive Use: The most important risk factor which is more apparent in women with long term use of high dosage OCPs. Anabolic-Androgenic Steroid (AAS) Use: Affecting males frequently and those men who take anabolic steroids to build muscles.
Metabolic Disorders: Fatty liver diseases, including obesity, metabolic syndrome, diabetes mellitus, and glycogen storage diseases (GSD) are associated with HCA formation.
Pregnancy: It has been attributed to hormonal changes that cause adenoma to enlarge and be inclined towards rupture.
Alcohol Consumption: Another modifiable risk factor is high alcohol consumption strictly linked to inflammatory HCAs.
HCA can present with acute complications such as:
Hemorrhage: In 30-45% of cases bleeding develops inside a tumor or in the peritoneal cavity. This risk is higher in larger adenomas and in pregnancy.
Rupture: Can cause severe condition known as acute hemorrhagic shock and presents clinically as sudden severe abdominal pain, hypotension and evident features of bleeding.
Hepatocellular Carcinoma (HCC)
Metastatic Cancer with Unknown Primary Site
Cholangiocarcinoma
Treatment Paradigm
Observation and Monitoring: Where the HCA is small and largely asymptomatic, measuring 4 to 5 centimetres or less and showing no signs of growth, observation might be adequate. Physical examination can be done periodically depending on the patient, but imaging (ultrasound, CT or MRI) should be obtained every 6-12 months.
Medical Management Oral Contraceptive Pill (OCP) Discontinuation: In females, cessation of OCP, led to the regression of the adenoma, especially in females with HCA due to hormonal factors.
Interventional Procedures Ablation Techniques: In bigger or symptomatic HCAs, other demanding procedures like radiofrequency ablation (RFA) or microwave ablation can be done. These are especially important for the patients who cannot undergo surgeries.
Transarterial Embolization (TAE): This procedure may be done in cases of symptomatic adenomas, particularly those adenomas with a propensity to bleed.
Surgical Intervention: For the potential application of surgery the following features are considered significant: Large HCAs (>4-5 cm) HCA that present symptoms, namely pain or haemorrhage. Atypical lipomatous tumor/was and lipomatous component of mixed malignant neoplasms with suspicious malignant transformation.
Liver Transplantation: For instance, if the patient has the adenoma in combination with cirrhosis, then liver transplantation can be done depends on the degree of liver pathology. Follow-Up Care: Routine imaging follow-up is essential for the monitoring of any sign of disease progression or reappearance of the adenoma.
Gastroenterology
Lifestyle Changes: Healthy weight and weight management is known to improve the prognosis of HCA; therefore, overweight and obese patients should try to lose weight. It also important to recommend that people should avoid or at least take limited alcohol intake to avoid harming their liver.
Physical Activity: Exercise also has therapeutic value in metabolic syndromes because it enhances metabolic functions and decreases hepatic steatosis and thus may slow the progression of HCA.
Hormonal Management: In women, loss of HCAs when they come off oral contraceptives can cause regression therefore, regular follow up should be done.
Comorbidity Management: The risks can be lowered by managing such factors as diabetes and metabolic syndrome by diet and drugs.
Gastroenterology
The discontinuation of OCPs forms a major component in the treatment of HCA particularly in women whose tumours have been established to be related to the use of these hormonal contraceptives. The adenomas in women with HCAs associated with OCP use are known to regress or even dissolve on cessation of the contraceptives. HCAs have been found to be self-limiting in about 27% of the cases and the size of lesion may reduce or disappear totally on cessation. OCPs especially those containing high estrogens increase the chances of developing HCAs. Discontinuation may assist in reducing this risk particularly in women who are prone to development of hormone induced liver lesion.
Gastroenterology
Surgical Resection: Endoscopic resection for adenoma is warranted in those with a size of adenoma greater than 5 cm, adenomas that are symptomatic or give rises to pain or bleeding and those for which malignancy is suspected. In case of a large or locally situated adenoma, partial hepatectomy may be done, that is, the adenoma and a rim of normal liver tissue are excised.
Laparoscopic Resection: This approach is used on smaller adenomas or in patients that would be fit for laparoscopic surgery. Laparoscopic surgery has fewer cuts, together with the aid of a video camera and long, thin instruments to remove the adenoma.
Radiofrequency Ablation (RFA): RFA is done if the adenomas are comparatively small (<3-4 cm), patient is not suitable for surgery or if the patient wants a minimally invasive treatment modality. This technique incorporates radiofrequency generated heat to cause ablation of the adenoma tissue.
Microwave Ablation (MWA): Like for RFA, MWA is used for small lesions and has favor of having shorter ablation times. It uses microwave energy in heating tissue and destroying the tumor. The study also pointed out the possible increased success rate of MWA compared to RFA for bigger tumor size.
Transarterial Chemoembolization (TACE): TACE has been described predominantly in the management of hepatocellular carcinoma but could be considered in the management of an HCA in patients with a bleeding risk or inoperable adenomas. This comprises the delivery of chemotherapy in the blood vessels feeding the adenoma with subsequent deployment of embolic agents, hence promoting ischemia.
Gastroenterology
The management of hepatocellular adenoma (HCA) involves several phases which play important steps in the process. Diagnosis is accomplished through imaging and biopsy in which the HCA is identified, and its features determined. The assessment phase is geared toward assessment of the patient’s general condition and risks factors such as, lifestyle and hormones. In the treatment phase, the management depends on the size of the adenoma and the symptoms of the patient; the options may include medicinal management, close follow up or surgical management. The second one is the post treatment period where the patient is closely followed up for signs of relapse and complications through imaging and symptoms. Lastly, the maintenance phase focuses on the regular follow-ups and necessary dietary changes in order to prevent the return of cancer besides caring for the liver health in general. All the phases play an important role in patient care, and successful outcomes as well as the overall management of HCA.
HCAs are benign liver tumors that are most often observed among women of childbearing age and that are highly associated with exposure to estrogens, including OCPs. An incidence of HCAs is 30-40 times more likely to occur among OCP users than non-users of the drugs. Even though HCAs are less common with OCP dosage reductions, obesity, metabolic syndrome, and steroids usage are now known causative agents. HCAs include glycogen storage diseases (GSDs), polycystic ovarian syndrome (PCOS), Klinefelter syndrome and others.
In men, obesity raises the risk of dying from hepatocellular carcinoma in patients with HCAs to a level beyond what metabolic syndrome does. HCAs can be solitary or multiple and can occasionally be larger than 20 cm in size Single β–catenin HCAs are at higher risk of developing both malignant transformation and hemorrhage.
Hepatocellular adenomas (HCAs) are very rare and are found in < 0.007- 0.012% of population. In women who do not use OCPs the incidence is calculated between 1 and 1.3 per million; for women using OCPs, the rate increases to 34 per million, with the risk being proportional to the period and the amount of estrogen. Although first- and second-generation contraceptives have been replaced by low-dose products, HCA have become more easily identified because of increased use of imaging techniques and the obesity and metabolic syndrome epidemics.
Regarding the gender distribution, the HCAs are not related to race, but the data from 1998 to 2008 present a male predominance in China because of the one-child policy and the non-availability of OCP, while female patients dominate the HCA cases in other zones. Approximately 90% of HCA cases are reported to have affected women whereas men, HCA is related with anabolic steroids and glycogen storage diseases.
Hepatocellular adenomas (HCAs) or hepatic adenomas are extremely rare and are reported in people with a prevalence of less than 0.007- 0.012% of the population. In women not using OC pills, the incidence rate is estimated at ranges from 1 to 1.3 women per one million women. For women on OCPs, this rate becomes roughly 34 per million, with the probability rising depending on the dose of estrogen and length of usage. Lower-dose contraceptives may now be seen more often because medical imaging is more widely used, obesity and metabolic syndrome are becoming more common.
They are not based on race, though a review from 1998-2008 showed a male majority among the Chinese, unlike females in other regions, probably due to birth control. HCA tumors mostly affect females with approximately 90% while in males, the tumors are associated with anabolic androgen steroids use and glycogen storage disease. Among them, the β-HCA subtype, commonly arising in males, has worse prognosis, and a higher incidence of malignancy. HCAs often occur in patients between 20 and 50 years of age.
In 1973, Baum et al suggested that OCPs had a relationship with HCAs, and both male and female hormones have been implicated in the formation of these tumours. HCAs are commonly associated with increased estrogen receptors in breast cancer, although this matter is still a subject of debate, as some HCAs may arise with no apparent risk factors. HCAs are assumed to be caused by genetic changes and environmental factors OCP and steatosis. Many genetic changes characterize different subtypes of HCA and all of them have different associations with the disease. The H-HCA subtype is inactivated by hepatocyte nuclear factor 1α and is related to diabetes and liver adenomatosis; the I-HCAs are associated with mutations in the JAK/STAT pathway, obesity, and alcohol use.
The β-HCAs involving the CTNNB1 gene yield higher risks of malignancy; such risks are accentuated in males, though the model is less statistically valid in male populations. More recent studies have even established up to eight HCA subtypes because knowledge of its progression is crucial. In glycogen storage diseases (GSD), type I-HCA is prevalent, and changes in diet might contribute towards reducing tumor progression. However, mutations on some chromosomes still predispose individuals to develop HCC. These hormones include insulin and glucagon and in some families with diabetes and liver adenomatosis HNF1α gene is mutated.
Chen et al. contributed to further knowledge in Hepatocellular adenoma (HCA) genesis in their work published in 2002 with the understanding that β-catenin is the Wnt signaling pathway. In their subsequent work, Bioulac-Sage and colleagues have designed a classification system based on the molecular characteristics that have been also confirmed by other authors. This system divides HCAs into four main types:
Hepatocyte Nuclear Factor-1α (HNF-1α) Inactivated Mutations: These mutations contribute to 35-40 percent of HCA incidences and include T-cell factor-1 gene responsible for liver differentiation, glucose, and lipid homeostasis. The lesions are steatotic, affect mainly women, and may be related to diseases such as MODY3 diabetes. A size of tumor below 5 cm does not contribute to the development of complications.
β-Catenin Activated Mutations: These adenomas form 15–20 percent of the cases and are associated with androgen, glycogen storage disease and familial adenomatous polyposis. These lesions are more likely to become malignant and are diagnosed by glutamine synthetase & aberrant β-catenin staining.
Inflammatory Hepatocellular Adenomas (IHCA): IHCA is found in 40-50% of the cases and is linked with risk factors including female sex, obesity, alcohol use, & conditions that cause systemic inflammation. Consequently, alteration of the IL-6 pathway in ADA-SCID results in unique vascular and sinusoidal features.
Unclassified Type: It is estimated that less than 10% of HCAs are of this kind; these present with liver-specific neoplastic tumors that have either lost marker such as CRP, SAA, β-catenin, and glutamine synthetase but express LFABP.
The outcome of patients HCA is slightly unclear and depends on the results of imaging and other invasive studies depending upon the tumor type. Cessation of OCPs may result in regression or resolution of some adenomas, however 27% HCAs may continue to rupture and have mortality between 5%-10%. The chances of cancer development are around 4.2%, and such risks remain present even after you cease using oral contraceptives. Patients are unlikely to fully eliminate HCA from their bodies. Around 25% of the females may have RUQ pain after delivery and hemorrhage is seen in 30 to 45 percent of women. Bleeding can occur within the tumor or into the peritoneal cavity; the risk of hemorrhage is proportional to the size of the lesion. Pregnancy is also associated with the increase in the size of HCA and the elevated risk of its rupture.
Abdominal Examination: The patient’s abdomen may be tender, or an enlarged abdomen may be present. Abdominal examination may be associated with right upper quadrant pain on palpation or percussion if there is hemorrhage or large tumor.
Hepatomegaly: Liver may be enlarged and tender, but in most cases of hepatic adenomas the lesion is not palpable.
Signs of Hemorrhage: In cases of acute hemorrhage probable manifestations of shock, the patient may present low blood pressure and tachycardia. Tenderness may be felt in the abdomen and there can be localised or generalised guarding or rebound tenderness if bleeding has occurred and caused peritoneal irritation.
Jaundice: However, jaundice could be seen in some cases of benign HCA but more frequently in malignant transformation or hepatic failures.
Oral Contraceptive Use: The most important risk factor which is more apparent in women with long term use of high dosage OCPs. Anabolic-Androgenic Steroid (AAS) Use: Affecting males frequently and those men who take anabolic steroids to build muscles.
Metabolic Disorders: Fatty liver diseases, including obesity, metabolic syndrome, diabetes mellitus, and glycogen storage diseases (GSD) are associated with HCA formation.
Pregnancy: It has been attributed to hormonal changes that cause adenoma to enlarge and be inclined towards rupture.
Alcohol Consumption: Another modifiable risk factor is high alcohol consumption strictly linked to inflammatory HCAs.
HCA can present with acute complications such as:
Hemorrhage: In 30-45% of cases bleeding develops inside a tumor or in the peritoneal cavity. This risk is higher in larger adenomas and in pregnancy.
Rupture: Can cause severe condition known as acute hemorrhagic shock and presents clinically as sudden severe abdominal pain, hypotension and evident features of bleeding.
Hepatocellular Carcinoma (HCC)
Metastatic Cancer with Unknown Primary Site
Cholangiocarcinoma
Treatment Paradigm
Observation and Monitoring: Where the HCA is small and largely asymptomatic, measuring 4 to 5 centimetres or less and showing no signs of growth, observation might be adequate. Physical examination can be done periodically depending on the patient, but imaging (ultrasound, CT or MRI) should be obtained every 6-12 months.
Medical Management Oral Contraceptive Pill (OCP) Discontinuation: In females, cessation of OCP, led to the regression of the adenoma, especially in females with HCA due to hormonal factors.
Interventional Procedures Ablation Techniques: In bigger or symptomatic HCAs, other demanding procedures like radiofrequency ablation (RFA) or microwave ablation can be done. These are especially important for the patients who cannot undergo surgeries.
Transarterial Embolization (TAE): This procedure may be done in cases of symptomatic adenomas, particularly those adenomas with a propensity to bleed.
Surgical Intervention: For the potential application of surgery the following features are considered significant: Large HCAs (>4-5 cm) HCA that present symptoms, namely pain or haemorrhage. Atypical lipomatous tumor/was and lipomatous component of mixed malignant neoplasms with suspicious malignant transformation.
Liver Transplantation: For instance, if the patient has the adenoma in combination with cirrhosis, then liver transplantation can be done depends on the degree of liver pathology. Follow-Up Care: Routine imaging follow-up is essential for the monitoring of any sign of disease progression or reappearance of the adenoma.
Gastroenterology
Lifestyle Changes: Healthy weight and weight management is known to improve the prognosis of HCA; therefore, overweight and obese patients should try to lose weight. It also important to recommend that people should avoid or at least take limited alcohol intake to avoid harming their liver.
Physical Activity: Exercise also has therapeutic value in metabolic syndromes because it enhances metabolic functions and decreases hepatic steatosis and thus may slow the progression of HCA.
Hormonal Management: In women, loss of HCAs when they come off oral contraceptives can cause regression therefore, regular follow up should be done.
Comorbidity Management: The risks can be lowered by managing such factors as diabetes and metabolic syndrome by diet and drugs.
Gastroenterology
The discontinuation of OCPs forms a major component in the treatment of HCA particularly in women whose tumours have been established to be related to the use of these hormonal contraceptives. The adenomas in women with HCAs associated with OCP use are known to regress or even dissolve on cessation of the contraceptives. HCAs have been found to be self-limiting in about 27% of the cases and the size of lesion may reduce or disappear totally on cessation. OCPs especially those containing high estrogens increase the chances of developing HCAs. Discontinuation may assist in reducing this risk particularly in women who are prone to development of hormone induced liver lesion.
Gastroenterology
Surgical Resection: Endoscopic resection for adenoma is warranted in those with a size of adenoma greater than 5 cm, adenomas that are symptomatic or give rises to pain or bleeding and those for which malignancy is suspected. In case of a large or locally situated adenoma, partial hepatectomy may be done, that is, the adenoma and a rim of normal liver tissue are excised.
Laparoscopic Resection: This approach is used on smaller adenomas or in patients that would be fit for laparoscopic surgery. Laparoscopic surgery has fewer cuts, together with the aid of a video camera and long, thin instruments to remove the adenoma.
Radiofrequency Ablation (RFA): RFA is done if the adenomas are comparatively small (<3-4 cm), patient is not suitable for surgery or if the patient wants a minimally invasive treatment modality. This technique incorporates radiofrequency generated heat to cause ablation of the adenoma tissue.
Microwave Ablation (MWA): Like for RFA, MWA is used for small lesions and has favor of having shorter ablation times. It uses microwave energy in heating tissue and destroying the tumor. The study also pointed out the possible increased success rate of MWA compared to RFA for bigger tumor size.
Transarterial Chemoembolization (TACE): TACE has been described predominantly in the management of hepatocellular carcinoma but could be considered in the management of an HCA in patients with a bleeding risk or inoperable adenomas. This comprises the delivery of chemotherapy in the blood vessels feeding the adenoma with subsequent deployment of embolic agents, hence promoting ischemia.
Gastroenterology
The management of hepatocellular adenoma (HCA) involves several phases which play important steps in the process. Diagnosis is accomplished through imaging and biopsy in which the HCA is identified, and its features determined. The assessment phase is geared toward assessment of the patient’s general condition and risks factors such as, lifestyle and hormones. In the treatment phase, the management depends on the size of the adenoma and the symptoms of the patient; the options may include medicinal management, close follow up or surgical management. The second one is the post treatment period where the patient is closely followed up for signs of relapse and complications through imaging and symptoms. Lastly, the maintenance phase focuses on the regular follow-ups and necessary dietary changes in order to prevent the return of cancer besides caring for the liver health in general. All the phases play an important role in patient care, and successful outcomes as well as the overall management of HCA.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Digital Certificate PDF
On course completion, you will receive a full-sized presentation quality digital certificate.
medtigo Simulation
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
medtigo Points
medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
Community Forum post/reply = 5 points
*Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.
All Your Certificates in One Place
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
